Reply to comment on “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”

  • Ahmed Sayed
    Faculty of Medicine, Ain Shams University, Cairo, Egypt
    Search for articles by this author
  • Omar M. Abdelfattah
    Department of Medicine, Morristown Medical Center, Atlantic Health System, Morristown, NJ, USA
    Search for articles by this author
  • Daniel Addison
    Corresponding author: Cardio-Oncology Program Division of Cardiology, Davis Heart & Lung Research Institute, Ohio State University 473 West 12th Avenue, Suite 200, Columbus, OH 43210, USA.
    Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, OH, USA

    Division of Cancer Control and Prevention, James Cancer Hospital and Solove Research Institute at the Ohio State University, Columbus, OH, USA
    Search for articles by this author
      We would like to thank Dr. Rizzo and Dr. Brandi for their constructive comments on our study. We concur with their statement on the importance of conducting head-to-head clinical trials that are sufficiently powered for the detection of clinically meaningful outcomes. We agree that although our analysis showed a meaningful benefit to cardioprotective therapies, it is not a substitute for such large prospective trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Omland T.
        • Heck S.L.
        • Gulati G.
        The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review.
        JACC: CardioOncology. 2022; 4: 19-37
        • Sayed A.
        • Abdelfattah O.M.
        • Munir M.
        • Shazly O.
        • Awad A.K.
        • Ghaith H.S.
        • et al.
        Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: a systematic review & bayesian network meta-analysis.
        Eur J Cancer. 2022; 169: 82-92
        • Makowski D.
        • Ben-Shachar M.S.
        • Chen S.H.A.
        • Ludecke D.
        Indices of effect existence and significance in the bayesian framework.
        Front Psychol. 2019; 10: 2767
        • Gongora C.A.
        • Drobni Z.D.
        • Silva T Quinaglia Araujo Costa
        • Zafar A.
        • Gong J.
        • Zlotoff D.A.
        • et al.
        Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
        JACC: Heart Failure. 2022;
        • Dickerson T.
        • Wiczer T.
        • Waller A.
        • Philippon J.
        • Porter K.
        • Haddad D.
        • et al.
        Hypertension and incident cardiovascular events following ibrutinib initiation.
        Blood. 2019; 134: 1919-1928

      Linked Article